Overview

A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome

Status:
Not yet recruiting

Trial end date:
2024-02-26

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate efficacy and safety of rozanolixizumab to treat adult study participants with severe fibromyalgia syndrome (FMS).

Phase:

Phase 2

Details

Lead Sponsor:

UCB Biopharma SRL

Treatments:

Rozanolixizumab